Conversant Bio has introduced formalin-fixed, paraffin-embedded cells samples annotated for the most common clinically relevant mutations, and matched FFPE and plasma sets.
With the mutation FFPE samples, Conversant Bio helps researchers by completing the screening process for them. This allows research teams to save significant time and resources and begin their projects as soon as they receive their FFPE. The point mutations Conversant Bio have identified include those involved in colorectal cancer (KRAS, BRAF, NRAS, PIK3CA); lung cancer (EGFR, KRAS); breast cancer (PIK3CA); and melanoma (BRAF, NRAS). The mutations have been confirmed by PCR using a proprietary lab-developed test in Conversant's CLIA lab.
Conversant is also offering matched FFPE and plasma sets for colorectal cancer, breast cancer, and kidney cancer. These matched sets come with patient data including demographic information, a pathology report, current treatments, and block QC information, and are collected under strict standard operating procedures with circulating tumor DNA and other biomarker comparisons in mind.